31.60

2.89% -0.94

After Hours: 31.60

Arvinas Inc (ARVN)

Overview News Price History Option Chain Discussions Forecast

Arvinas Inc stock is currently priced at $31.60, with a 24-hour trading volume of 627.39K. It has seen a -2.89% decreased in the last 24 hours and a -22.30% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $32.96 pivot point. If it approaches the $30.77 support level, significant changes may occur.

Previous Close:

$32.54

Open:

$32

24h Volume:

627.39K

Market Cap:

$2.16B

Revenue:

$78.50M

Net Income/Loss:

$-367.30M

P/E Ratio:

-5.653

EPS:

-5.59

Net Cash Flow:

$-350.70M

1W Performance:

-7.84%

1M Performance:

-22.30%

6M Performance:

+118.99%

1Y Performance:

+16.95%

1D Range:

$30.91

$32.13

52W Range:

$13.57

$53.08

Arvinas Inc Stock (ARVN) Company Profile

Name

Arvinas Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

203-535-1456

Address

5 Science Park, 395 Winchester Avenue, New Haven, CT

Employee

Twitter

@ArvinasInc

Next Earnings Date

2024-05-03

Latest SEC Filings

ARVN's Discussions on Twitter

Arvinas Inc Stock (ARVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-14-24	Downgrade	Citigroup	Buy → Neutral
Feb-01-24	Initiated	Goldman	Buy
Dec-19-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-06-23	Upgrade	Jefferies	Hold → Buy
Nov-20-23	Upgrade	Guggenheim	Neutral → Buy
Oct-23-23	Upgrade	Wedbush	Neutral → Outperform
Jun-26-23	Resumed	Oppenheimer	Outperform
Jan-12-23	Downgrade	Guggenheim	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-09-22	Initiated	Barclays	Overweight
Jun-21-22	Initiated	Jefferies	Hold
May-09-22	Downgrade	Wedbush	Outperform → Neutral
Apr-28-22	Initiated	Credit Suisse	Outperform
Apr-06-22	Initiated	Morgan Stanley	Equal-Weight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Overweight
Jan-19-22	Initiated	Goldman	Buy
Dec-07-21	Initiated	Cowen	Outperform
Oct-14-21	Initiated	SVB Leerink	Outperform
Sep-30-21	Initiated	Stifel	Buy
Sep-09-21	Initiated	BofA Securities	Buy
May-21-21	Initiated	UBS	Buy
Apr-21-21	Initiated	Truist	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Dec-14-20	Upgrade	Oppenheimer	Perform → Outperform
Jun-01-20	Upgrade	Citigroup	Neutral → Buy
May-12-20	Initiated	Oppenheimer	Perform
Dec-19-19	Initiated	H.C. Wainwright	Buy
Nov-25-19	Initiated	Guggenheim	Buy
Oct-24-19	Upgrade	Goldman	Neutral → Buy
Sep-25-19	Initiated	Wedbush	Outperform
Sep-12-19	Initiated	BMO Capital Markets	Outperform
Aug-06-19	Initiated	Cantor Fitzgerald	Overweight
Jun-05-19	Downgrade	Citigroup	Buy → Neutral
Apr-12-19	Initiated	Evercore ISI	Outperform
Oct-22-18	Initiated	Citigroup	Buy
Oct-22-18	Initiated	Goldman	Neutral
Oct-22-18	Initiated	Piper Jaffray	Overweight

View All

Arvinas Inc Stock (ARVN) Latest News

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

GlobeNewswire Inc.

Is Arvinas (ARVN) Stock a Solid Choice Right Now?

Zacks Investment Research

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire Inc.

Arvinas Inc Stock (ARVN) Financials Data

Arvinas Inc (ARVN) Revenue 2024

ARVN reported a revenue (TTM) of $78.50 million for the quarter ending December 31, 2023, a -40.21% decline year-over-year.

Arvinas Inc (ARVN) Net Income 2024

ARVN net income (TTM) was -$367.30 million for the quarter ending December 31, 2023, a -30.02% decrease year-over-year.

Arvinas Inc (ARVN) Cash Flow 2024

ARVN recorded a free cash flow (TTM) of -$350.70 million for the quarter ending December 31, 2023, a -25.12% decrease year-over-year.

Arvinas Inc (ARVN) Earnings per Share 2024

ARVN earnings per share (TTM) was -$6.50 for the quarter ending December 31, 2023, a -22.18% decline year-over-year.

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.